Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...
Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended its program.
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...
During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be ...
NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") Such investors are advised to contact ...
What Happened? On December 30, 2024, after market hours, Sangamo disclosed that Pfizer Inc. ("Pfizer") had notified the Company of its termination of a partnership to develop a hemophilia A gene ...